THE TRUTH ABOUT: Obsv - Caught on Camera

ObsEva SA (NASDAQ:OBSV) has announced additional efficacy results from the Phase 3 EDELWEISS 3 trial of linzagolix for moderate-to-severe endometriosis-associated pain (EAP). The results build upon the positive topline results announced in January 2022. Two dose regimens were tested, a 200 mg once-daily dose of linzagolix combined with hormonal add-back therapy (ABT) and a…